BioCatalystWatch
VRTXWorkspace / VRTX / OverviewCompany library
VERTEX PHARMACEUTICALS INC / MA logo

VERTEX PHARMACEUTICALS INC / MA

VERTEX PHARMACEUTICALS INC / MA (VRTX)

Website

Price
Market cap
Next catalystNov 30, 2026povetacicept · Regulatory decisionSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

VX-993

NaV1.8

PreINDP1P2P3FilingApproved
Upcoming / outlook

povetacicept

BAFF × APRIL

PreINDP1P2P3FilingApproved
Upcoming / outlook

JOURNAVX® (suzetrigine)

Small molecule

NaV1.8

PreINDP1P2P3FilingApproved
Upcoming / outlook

APOL1

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

VX-670

DMPK transcript repeats

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

VX-670

DMPK transcript repeats

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

VX-993

NaV1.8

PreINDP1P2P3FilingApproved
Upcoming / outlook

JOURNAVX® (suzetrigine)

Small molecule

NaV1.8

PreINDP1P2P3FilingApproved
Upcoming / outlook

povetacicept

BAFF × APRIL

PreINDP1P2P3FilingApproved
Upcoming / outlook

APOL1

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

JOURNAVX® (suzetrigine)

Small molecule

NaV1.8

PreINDP1P2P3FilingApproved
JOURNAVX® (suzetrigine)

Small molecule

NaV1.8

PreINDP1P2P3FilingApproved
povetacicept

BAFF × APRIL

PreINDP1P2P3FilingApproved
VX-993

NaV1.8

PreINDP1P2P3FilingApproved
VX-993

NaV1.8

PreINDP1P2P3FilingApproved
povetacicept

BAFF × APRIL

PreINDP1P2P3FilingApproved

ACTH receptor

PreINDP1P2P3FilingApproved
lumacaftor/ivacaftor

F508del-CFTR

PreINDP1P2P3FilingApproved

Partner / License out

Approved / commercial

JOURNAVX® (suzetrigine)

Small molecule

NaV1.8

Approved

PreINDP1P2P3FilingApproved
Upcoming / outlook

SST2

PreINDP1P2P3FilingApproved
Upcoming / outlook

CFTR

Approved

PreINDP1P2P3FilingApproved

History / paused

PreINDP1P2P3FilingApproved

ACTH receptor

PreINDP1P2P3FilingApproved

ATR

PreINDP1P2P3FilingApproved

Rho

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

VRTX PR & News

PR & News

VRTX SEC archive